Research & Innovation Presentation. Dr Elizabeth Price R&I Director

Transkript

1 Research & Innovation Presentation Dr Elizabeth Price R&I Director

2 Introduction Research is an integral part of NHS activity and is essential for finding new and better ways of preventing, diagnosing and treating illness. Involvement in research brings a number of benefits to the Trust: Early access to new interventions Improvement to patient outcomes Opportunities for staff development Income generation The Research and Innovation team s role is to enable clinicians to perform research safely, ethically and efficiently. This in turn allows them to focus on the care of their patients and the quality of the data they collect.

3 Current Climate Generic research teams to maximise efficiency and use of resources Increasing use of Allied Health Professionals and Practitioners working closely with Principle Investigators NIHR targets now require us to demonstrate delivery of research across all specialities within the Trust. R&I Team assess feasibility, manage approvals process and support delivery

4 Team Structure

5 Current Trials 20 potential trials in set up phase 69 open trials 36 active Principal Investigators 92 trials in follow up (365 cancer patients in long term follow-up) 10,612 patients screened (for trials currently open or in follow up) 50% of screened patients were recruited.

6 Open Trials by Speciality Trials Speciality Open Anaesthesia, Perioperative Medicine and Pain Management 2 Blood 1 Cancer 18 Cardiovascular 12 Critical Care 3 Dementias and Neurodegenerative Diseases 1 Diabetes 2 Genetics & Congenital Disorders 1 Health services and delivery research 1 Infection 1 Meds for Children 4 Mental Health 1 Musculoskeletal 11 Obstetrics & Gynaecology 1 Ophthalmology 1 Oral and Gastrointestinal 1 Public Health 1 Renal and Urogenital 2 Respiratory 2 Stroke 3

7 Trials Opened Financial Year Trials Opened Commercial Non Commercial 2017/ / /

8 Total Recruitment Financial Year Patients Recruited 2017/ / /

9 GWH 2017/18 Successes Financial Year Trials where GWH First Recruiter 2017/ / /18 12 GWH was the first European site to perform a pulmonary artery sensor implant for the CardioMEMS study. However, we were the first site Globally to consent to this study (Cardiology) GWH recruited the first SERENA patient by any UK site. (Rheumatology) GWH was the first UK site to screen and recruit a patient for the GSK trial. (Rheumatology)

10 Contribution to the Trust Provision of equipment Cardiology monitor (c. 700) Dyson fans for Physiology (c. 1,000) Ice maker for Outpatients (c. 120) Centrifuge for Pathology (c. 5,700) Hot water outlet for the Breast Centre (c. 1,700) Imaging software for Radiology ( 15,000) Exam fees and accreditation (c. 1,000) Tibial nerve stimulators for Obs & Gynae (c. 10,000) Over 35,000 of equipment provided to the Trust in the last 18 months

11 Contribution to the Trust Provision of Staff Pharmacy 2 FTE. Pathology 1 FTE. Contribution to departmental budget for staff in Histopathology and Radiology. In conjunction with the Academy, R&I is supporting an innovation in the 2018/19 financial year to provide funding for 3 Band-5 dual roles encompassing both ward and research work.

12 Opportunities Increase commercial studies Engage with new consultants and use R&I to attract consultants/clinical staff Long term dedicate area for trials which would generate more income

13 Any Questions?